Advertisement
COGT vs ENGN
Which Stock Would AI Choose? Cogent Biosciences (COGT) vs. enGene Therapeutics (ENGN) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: Between the two names, the model currently favors COGT, which shows stronger trend consistency, more mature clinical catalysts, and greater relative momentum than ENGN.
- COGT has re-rated sharply upward following positive late-stage data, with multiple regulatory filings now under U.S. Food and Drug Administration (FDA) review.
- ENGN trades near the low end of its 52-week range after a drawdown triggered by weaker-than-expected interim data, leaving sentiment more cautious.
- The two companies have fundamentally different risk profiles: COGT is a late-stage, pre-commercial oncology franchise, while ENGN is a single-asset, earlier-stage gene-therapy program.
- For more detail on each name, explore COGT Major News and COGT Today's Price Move, plus ENGN Major News and ENGN Today's Price Move.
- To see how automated systems are positioning across the market, visit Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies that, despite sharing a sector, sit at very different points in their development and market cycles. Cogent Biosciences (NASDAQ: COGT) is advancing a precision oncology program toward potential commercialization, while enGene Therapeutics (NASDAQ: ENGN) is developing a non-viral gene therapy for bladder cancer still years from a potential launch. Traders focused on relative performance and momentum, as well as investors weighing clinical catalysts against balance-sheet and regulatory risk, may find this comparison useful. The contrast between a stock in a strong uptrend and one recovering from a steep drawdown illustrates how market positioning and sentiment can diverge even within the same industry.
COGT Overview and Recent Performance
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib, targets KIT mutations in systemic mastocytosis and gastrointestinal stromal tumors (GIST), a rare form of digestive-tract cancer. Recent market activity has been defined by positive Phase 3 PEAK data showing that bezuclastinib combined with sunitinib extended median progression-free survival (PFS, the time a patient lives without the disease worsening) to 16.5 months versus 9.2 months for sunitinib alone. That result drove a substantial re-rating, with shares up several hundred percent over the trailing year. The company has since submitted multiple New Drug Applications (NDAs) to the FDA, including one granted Priority Review for GIST, and ended recent quarters with roughly $900 million in cash, funding operations into 2028. Analyst consensus remains broadly favorable, and market capitalization now exceeds $5 billion.
ENGN Overview and Recent Performance
enGene Therapeutics, formerly enGene Holdings, is a clinical-stage biotechnology company developing non-viral genetic medicines delivered to mucosal tissues. Its lead asset, detalimogene voraplasmid, is being studied for high-risk, non-muscle invasive bladder cancer (NMIBC) in the Phase 2 LEGEND trial. Recent market activity has been volatile: shares fell sharply after interim data from a revised pivotal cohort showed a complete response (CR) rate below earlier expectations, and the stock now trades near the low end of its 52-week range, with a market capitalization of roughly $120 million. Management plans to report maturing durability data and to initiate a Biologics License Application (BLA) filing in late 2026, with a potential FDA decision in 2027. The company holds about $266 million in cash, but its single-asset profile and a history of equity dilution have contributed to a cautious sentiment among investors and analysts, several of whom have trimmed price targets in recent months.
Trending AI Robots
Tickeron operates a broad ecosystem of AI-powered trading bots, with hundreds of automated systems actively trading thousands of different tickers. Because only a subset of these bots is well-suited to prevailing market conditions at any given time, Tickeron curates a dedicated Trending AI Robots page to surface those currently demonstrating the most relevant performance. The available bots span a wide range of trading styles, strategies, timeframes, and performance statistics, and each is configured to trade its own set of tickers. This variety lets users compare approaches and identify systems aligned with their own risk tolerance and objectives. For traders and investors seeking a data-driven perspective on market positioning, exploring the Trending AI Robots section can offer a useful complement to traditional research.
Head-to-Head Comparison
The clearest contrast between these two names is stage of development and market positioning. COGT has progressed to multiple regulatory filings, a larger cash base, and positive pivotal data, which supports a more stable upward trend and a premium valuation. ENGN, by comparison, is a single-asset program facing a binary clinical and regulatory path, with a much smaller market capitalization and a share price that has been weighed down by dilution and weaker interim data. Growth drivers also differ: COGT's value hinges on potential approvals and commercial launches across several indications, whereas ENGN's hinges on one drug, one indication, and the durability of its response data. On risk factors, both are pre-revenue and unprofitable, but ENGN's concentration risk and near-delisting price levels are more pronounced. In terms of sector exposure, both operate in biotechnology, yet COGT's oncology franchise is broader and further advanced. Market sentiment currently rewards COGT's momentum and clearer catalysts while discounting ENGN's uncertainty.
Tickeron AI Verdict
Based on observable factors such as trend consistency, momentum, catalyst maturity, and relative stability, Tickeron's AI would likely favor COGT over ENGN in the current environment. COGT's sustained uptrend, positive late-stage data, and advancing regulatory milestones present a more consistent technical and fundamental profile, while ENGN's downtrend and single-asset binary risk weigh on its relative positioning. This assessment is probabilistic rather than definitive, reflecting a comparative view of the two stocks rather than a forecast of future prices. Investors should weigh these structural differences against their own objectives and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COGT is a Hold and ENGN is a Buy.
COGT's RSI Indicator ascending out of oversold territory
The RSI Indicator for COGT moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 23 of the 25 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for COGT just turned positive on October 19, 2026. Looking at past instances where COGT's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
Following a +13.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where COGT advanced for three days, in 229 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COGT as a result. In 79 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
COGT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
COGT broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for COGT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. COGT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.742) is normal, around the industry mean (3.498). P/E Ratio (-14.650) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ENGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
ENGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 21 of 23 cases where ENGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENGN's RSI Indicator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ENGN as a result. In 48 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for ENGN just turned positive on November 04, 2026. Looking at past instances where ENGN's MACD turned positive, the stock continued to rise in 21 of 27 cases over the following month. The odds of a continued upward trend are 78%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENGN advanced for three days, in 129 of 152 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ENGN moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENGN crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ENGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.509) is normal, around the industry mean (3.498). P/E Ratio (-0.845) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ENGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
COGT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 28 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 40 | |
P/E GROWTH RATING 1..100 | 23 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| COGT | ENGN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Advances ODDS (%) | 3 days ago 84% | 3 days ago 85% |
| Declines ODDS (%) | 10 days ago 82% | 20 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COGT’s FA Score shows that 2 FA rating(s) are green while ENGN’s FA Score has 0 green FA rating(s).
- COGT’s FA Score: 2 green, 3 red.
- ENGN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COGT’s TA Score shows that 3 TA indicator(s) are bullish while ENGN’s TA Score has 5 bullish TA indicator(s).
- COGT’s TA Score: 3 bullish, 6 bearish.
- ENGN’s TA Score: 5 bullish, 5 bearish.
Price Growth
COGT (@Biotechnology) experienced а +1.87% price change this week, while ENGN (@Biotechnology) price change was +3.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
COGT is expected to report earnings on Mar 16, 2027.
ENGN is expected to report earnings on Dec 28, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
COGT and
Correlation & Price change
A.I.dvisor indicates that over the last year, COGT has been closely correlated with DMRA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if COGT jumps, then DMRA could also see price increases.
| Ticker / NAME | Correlation To COGT | 1D Price Change % | ||
|---|---|---|---|---|
| COGT | 100% | -5.66% | ||
| DMRA - COGT | 76% Closely correlated | +0.33% | ||
| ENGN - COGT | 47% Loosely correlated | -5.65% | ||
| MLYS - COGT | 42% Loosely correlated | -1.83% | ||
| REPL - COGT | 42% Loosely correlated | +4.58% | ||
| VERA - COGT | 39% Loosely correlated | -1.89% | ||
More | ||||
ENGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To ENGN | 1D Price Change % | ||
|---|---|---|---|---|
| ENGN | 100% | -5.65% | ||
| TRDA - ENGN | 75% Closely correlated | +11.94% | ||
| COGT - ENGN | 48% Loosely correlated | -5.66% | ||
| PHAR - ENGN | 43% Loosely correlated | +0.46% | ||
| INSM - ENGN | 42% Loosely correlated | +2.92% | ||
| ASBP - ENGN | 36% Loosely correlated | +0.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XLCI | 22.69 | 0.09 | +0.38% |
| State Street Communication Services Select Sector SPDR Premium Income ETF (XLCI) | |||
| OPER | 100.17 | 0.01 | +0.01% |
| ClearShares Ultra-Short Maturity ETF (OPER) | |||
| NVBT | 40.07 | -0.10 | -0.25% |
| AllianzIM U.S. Equity Buffer10 Nov ETF (NVBT) | |||
| AVIG | 39.96 | -0.28 | -0.70% |
| Avantis Core Fixed Income ETF (AVIG) | |||
| ICOP | 47.94 | -1.52 | -3.07% |
| iShares Copper and Metals Mining ETF (ICOP) | |||